Short answer
Definitive Healthcare Corp. (DH) filed an 8-K current report with the SEC on September 2, 2026 reporting Item 5.02 (Departure/Election of Directors or Officers), Item EX-99.1 (Exhibit EX-99.1). Clay Ritchey appointed CEO and director effective September 8, 2026, replacing Kevin Coop.
Definitive Healthcare Corp. 8-K event analysis
AI summary of each reported item and its exhibits
Item 5.02 · Departure/Election of Directors or Officers
- Clay Ritchey appointed CEO and director effective September 8, 2026, replacing Kevin Coop
- Healthcare technology executive with prior CEO experience at Verato, Evariant, and Equinox Healthcare
- Compensation includes $500,000 salary, 87.5% target bonus, and minimum $2,000,000 annual equity target
- Initial equity award totals $4,000,000, including $2,600,000 time-based and $1,400,000 performance-based RSUs
- Coop’s departure classified without Cause, with separation terms still pending disclosure
Item EX-99.1 · Exhibit EX-99.1
- Clay Ritchey appointed CEO and director effective September 8, 2026
- Kevin Coop departed both roles effective August 31, 2026 after serving as CEO since June 2024
- Leadership change targets a return to growth under an executive with more than 25 years of healthcare experience
- Upcoming AI-powered platform combines healthcare data, conversational AI, and workflows
- Execution risk remains around leadership transition, customer growth, platform demand, and AI rollout
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Definitive Healthcare Corp. 8-K filings
Get the next DH 8-K as it lands
Follow DH for push alerts, or ask the research agent what this filing means.